文献速递神经乳腺MR

DSC灌注MR相对脑血容量与乳腺癌脑转移HER2状态的相关性

Association of Relative Cerebral Blood Volume from Dynamic Susceptibility Contrast-Enhanced Perfusion MR with HER2 Status in Breast Cancer Brain Metastases.
PubMed 文献 · Acad Radiol · 2022-12-21

本研究纳入14例经组织学证实的乳腺癌脑转移患者,术前接受DSC灌注MR检查,比较HER2阳性与阴性病灶的rCBV。结果显示HER2阳性病灶rCBV显著高于阴性病灶(8.02 vs 3.97,p=0.001),rCBV鉴别HER2状态的AUC为0.98;以4.8为阈值时准确率93%、敏感度100%、特异度86%。结论认为rCBV可能有助于无创识别乳腺癌脑转移的HER2状态,但需大样本前瞻性试验验证。

要点

  • 乳腺癌脑转移HER2阳性病灶rCBV显著高于阴性病灶。
  • rCBV鉴别HER2状态AUC达0.98,阈值4.8时准确率93%。
  • 该指标尚属初步证据,需前瞻性大样本验证后方可用于临床。

核心结论

  • rCBV可能有助于识别乳腺癌脑转移的HER2状态,但需在大样本前瞻性试验中验证。

研究设计与样本

  • 单中心回顾性横断面研究,经IRB批准并豁免知情同意,符合HIPAA要求。
  • 纳入2011-2021年14例女性患者共14个经组织学证实的乳腺癌脑转移病灶,平均年龄56岁(范围32-81岁)。
  • 所有病灶均有术前DSC灌注MR及手术切除/活检脑标本的HER2分析结果。
  • 采用Mann-Whitney检验比较rCBV,并用ROC分析评估rCBV识别HER2状态的效能。

关键影像表现/征象

  • HER2阳性乳腺癌脑转移的rCBV显著高于HER2阴性病灶(8.02 vs 3.97,U=48.00,p=0.001)。

诊断标准与关键数值

  • rCBV鉴别HER2阳性与阴性病灶的AUC为0.98(标准误=0.032,p<0.001)。
  • 最大准确率rCBV阈值为4.8,对应准确率93%(13/14)、敏感度100%(7/7)、特异度86%(6/7)。

临床应用与阅片要点

  • 在乳腺癌脑转移患者的DSC灌注MR阅片中,可关注rCBV值,较高rCBV提示HER2阳性的可能性大。
  • 阈值4.8可作为初步参考,但须结合病理HER2结果,不可单独用于治疗决策。

局限性

  • 样本量小(仅14例14个病灶),为单中心回顾性研究,结果需大样本前瞻性试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: With the development of HER2-directed therapies, identifying non-invasive imaging biomarkers of HER2 expression in breast cancer brain metastases has become increasingly important. The purpose of this study was to investigate whether relative cerebral blood volume (rCBV) from dynamic susceptibility contrast-enhanced (DSC) perfusion MR could help identify the HER2 status of breast cancer brain metastases.

MATERIALS AND METHODS: With IRB approval for this HIPAA-compliant cross-sectional study and a waiver of informed consent, we queried our institution's electronic medical record to derive a cohort of 14 histologically proven breast cancer brain metastases with preoperative DSC perfusion MR and HER2 analyses of the resected/biopsied brain specimens from 2011-2021. The rCBV of the lesions was measured and compared using Mann-Whitney tests. Receiver operating characteristic analyses were performed to evaluate the performance of rCBV in identifying HER2 status.

RESULTS: The study cohort was comprised of 14 women with a mean age of 56 years (range: 32-81 years) with a total of 14 distinct lesions. The rCBV of HER2-positive breast cancer brain metastases was significantly greater than the rCBV of HER2-negative lesions (8.02 vs 3.97, U=48.00, p=0.001). rCBV differentiated HER2-positive lesions from HER2-negative lesions with an area under the curve of 0.98 (standard error=0.032, p<0.001). The accuracy-maximizing rCBV threshold (4.8) was associated with an accuracy of 93% (13/14), a sensitivity of 100% (7/7), and a specificity of 86% (6/7).

CONCLUSION: rCBV may assist in identifying the HER2 status of breast cancer brain metastases, if validated in a large prospective trial.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Young, Ressler, Shiroishi, et al. Association of Relative Cerebral Blood Volume from Dynamic Susceptibility Contrast-Enhanced Perfusion MR with HER2 Status in Breast Cancer Brain Metastases. Acad Radiol. 2022. PMID: 36549990. doi:10.1016/j.acra.2022.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。